FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

2019 ◽  
Author(s):  
Keyword(s):  
Metastatic Nsclc

scholarly journals 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type

2020 ◽  
Vol 31 ◽  
pp. S838 ◽  
Author(s):  
K. Nakagawa ◽  
E. Nadal ◽  
E.B. Garon ◽  
M. Nishio ◽  
T. Seto ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Metastatic Nsclc ◽  
Egfr Mutated ◽  
Mutation Type

scholarly journals FP12.06 GRIm-Score Variations Predict Outcome in Metastatic NSCLC Patients Treated with First-Line Pembrolizumab

2021 ◽  
Vol 16 (3) ◽  
pp. S219
Author(s):  
E. Lenci ◽  
L. Cantini ◽  
S. Rinaldi ◽  
F. Pecci ◽  
V. Cognigni ◽  
...  
Keyword(s):  
First Line ◽  
Metastatic Nsclc ◽  
Nsclc Patients

Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC

2021 ◽  
Author(s):  
Erika Rijavec ◽  
Alice Indini ◽  
Michele Ghidini ◽  
Gianluca Tomasello ◽  
Monica Cattaneo ◽  
...  
Keyword(s):  
Line Treatment ◽  
First Line ◽  
Metastatic Nsclc ◽  
First Line Treatment

scholarly journals A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG‐ACRIN EA5181 study

2021 ◽  
Author(s):  
John M Varlotto ◽  
Zhuoxin Sun ◽  
Bonnie Ky ◽  
Jenica Upshaw ◽  
Sharyn I Katz ◽  
...  
Keyword(s):  
Metastatic Nsclc
Sign in / Sign up

Export Citation Format

Share Document